After oncology wind-down, TG’s pivot to MS faces setback as FDA pushes approval decisionnews2022-05-31T12:53:56+00:00May 31st, 2022|FierceBiotech|
Bouncing back from late-phase fail, Minoryx pockets €51M to guide rare disease drug to marketnews2022-05-31T12:22:48+00:00May 31st, 2022|FierceBiotech|
GSK strikes $3.3B Affinivax buyout to MAP out challenge to Pfizer’s blockbuster pneumococcal vaccinenews2022-05-31T09:20:01+00:00May 31st, 2022|FierceBiotech|
RhoVac’s prostate cancer vaccine phase 2 failure forces biotech to cut costsnews2022-05-30T10:52:39+00:00May 30th, 2022|FierceBiotech|
ASCO: Mirati cedes to Amgen’s Lumakras on durability in tight KRAS battlenews2022-05-27T13:05:08+00:00May 27th, 2022|FierceBiotech|
Addex’s eyelid data fail to make clear case for spasm expansionnews2022-05-27T11:43:12+00:00May 27th, 2022|FierceBiotech|
Iovance sinks 50% as pivotal cell therapy data disappoint investors, but approval plan pushes ahead anywaynews2022-05-27T08:57:27+00:00May 27th, 2022|FierceBiotech|
ASCO: Genentech touts bispecific data for DLBCL, calling it ‘groundbreaking’ for heavily pretreated patientsnews2022-05-27T00:20:55+00:00May 27th, 2022|FierceBiotech|
Chutes & Ladders—Alchemab CEO resigns immediately citing ‘personal reasons’news2022-05-26T20:22:01+00:00May 26th, 2022|FierceBiotech|
ASCO: Merck’s Keytruda combo data could spark hope for lymphoma patients who lack optionsnews2022-05-26T17:00:26+00:00May 26th, 2022|FierceBiotech|
